AUTHORS
Zhiming Li, MD, Keshu Zhou, PhD2, Zengjun Li, MD3, Hongmei Jing I, MD4, Liqun Zou, MD5, Jie Jin, MD6, Wei Yang7, Yajun Li8, Li Wang9, Wuping Li10, Jian Ge, PhD11, Shuhua Yi, DO12, Guohui Cui13, Hongxiang Wang14, Zhongxing Jiang15, Yanli Yang16, Shaoyuan Wang, MD17, Xiaohan Li18, Nuo Chen19, Weige Wang, MD, PhD20, Renbin Zhao, PhD21, Lu-Gui Qiu, PhD22
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Henan Cancer Hospital, Zhengzhou, China
3 Cancer Hospital of Shandong First Medical University, Jinan, China
4 Peking University Third Hospital, Beijing, China
5 West China Hospital of Sichuan University, Chengdu, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Shengjing Hospital of China Medical University, Shenyang, China
8 Hunan Cancer Hospital, Changsha, China
9 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
10 Jiangxi Cancer Hospital, Nanchang, China
11 The First Affiliated Hospital of Anhui Medical University, Hefei, China
12 Institute of Hematology & Blood Diseases Hospital, Tianjin, China
13 Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 The Central Hospital of Wuhan, Wuhan, China
15 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
16 The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
17 Fujian Medical University Union Hospital, Fuzhou, China
18 innocare pharma limited, Beijing, China
19 InnoCare Pharma Limited, Beijing, China
20 InnoCare Pharma Limited, Beijing, China
21 InnoCare Pharma Limited, Beijing, China
22 Institute of Hematology & Blood Diseases Hospital, Tianjin, China
ABSTRACT
Background: Single-agent inhibition with Bruton tyrosine kinase (BTK) or B-cell lymphoma 2 (BCL2) inhibitors achieves limited deep remissions or carries safety liabilities, such as tumor lysis syndrome (TLS) with first-generation BCL2 inhibitors like venetoclax. Combining BTK and BCL2 inhibitors provides vertical pathway inhibition and synergistic antitumor activity. Orelabrutinib is a highly selective, second-generation BTK inhibitor approved for relapsed/refractory (R/R) mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Mesutoclax (ICP-248) is a novel, potent, selective BCL2 inhibitor with optimized pharmacokinetic properties and single-agent activity in R/R MCL and CLL/SLL. Here, we report the efficacy and safety outcomes of mesutoclax combined with orelabrutinib, with or without rituximab, from an ongoing Phase 1 trial (NCT05728658).
Methods: Patients with R/R MCL, R/R MZL, R/R CLL/SLL, or treatment-naïve (TN) MCL were enrolled into combination treatment cohorts. All patients received oral orelabrutinib 150 mg once daily continuously. Mesutoclax was escalated to a target dose of 125 mg daily using either a weekly or daily dose ramp-up schedule. Patients with R/R MCL and R/R MZL received concurrent daily mesutoclax plus orelabrutinib starting Cycle 1 Day 1. Patients with R/R CLL/SLL received either continuous mesutoclax plus rituximab or 2 cycles of orelabrutinib induction prior to mesutoclax ramp-up. Patients with TN MCL received 2 cycles of orelabrutinib plus rituximab induction before starting mesutoclax. Rituximab (375 mg/m²) was administered on Day 1 of Cycles 1–6 (6 cycles total).
Results: As of July 24, 2026, 77 patients received combination therapy: R/R MCL (n=21), R/R MZL (n=20), R/R CLL/SLL (n=16), and TN MCL (n=20). Among 59 patients with ≥1 post-baseline response assessment, the overall response rate (ORR) was 98.3% (58/59). Complete response rates (CRR) were 85.0% for R/R MCL, 55.6% for R/R MZL, 11.1% for R/R CLL/SLL, and 50.0% for TN MCL. Notably, TN MCL patients achieved a 50.0% CRR after only 2 cycles of induction therapy. Six-month progression-free survival (PFS) rates were 100% in R/R MCL and 90.6% in R/R MZL. All subgroups remain on active treatment with ongoing response durability assessments.
At the safety cutoff (June 29, 2026; n=61 safety-evaluable), combination regimens exhibited favorable tolerability with no new safety signals compared to single-agent profiles. Treatment-emergent adverse events (TEAEs) were predominantly Grade 1–2. No TEAEs led to treatment discontinuation or death. Grade ≥3 TEAEs included neutropenia (18.3%) and thrombocytopenia (5.0%), occurring primarily in rituximab-containing CLL/SLL arms. Crucially, no clinical or laboratory TLS was reported, including CLL/SLL patients managed with daily mesutoclax ramp-up.
Conclusions: The combination of mesutoclax and orelabrutinib ± rituximab demonstrated high overall response rates, rapid deep remissions, and favorable tolerability across diverse B-cell malignancies. The absence of TLS validates the safety of the mesutoclax ramp-up strategy. These novel, chemo-free combinations represent a highly promising therapeutic strategy for B-cell lymphomas, supporting continued clinical development and trial expansion.
DISCLOSURES
Zhiming Li, MD: No relevant conflicts of interest to declare.